Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
VAXIGRIP TETRA (Sanofi-Aventis Australia Pty Ltd)
Product name
VAXIGRIP TETRA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
168 working days (255)
Active ingredients
Inactivated Quadrivalent Influenza Vaccine (Split Virion) influenza virus haemagglutinin
Registration type
NCE/NBE
Indication
VAXIGRIP TETRA (suspension for injection) is indicated for active immunisation of adults and children from 6 months of age and older for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine.